What is Venus Remedies Ltd (VENUSREM) share price return in the past 10 years?

Venus Remedies Ltd share price has appreciated 33.9% annually (CAGR) over the past ten years.

What is the share price of Venus Remedies Ltd (VENUSREM)?

Company share prices are keep on changing according to the market conditions. The current trading price of Venus Remedies Ltd (VENUSREM) on 04-Jun-2026 16:59:59 at 16:59 is 1559.15.

What is the P/E ratio of Venus Remedies?

The latest standalone P/E ratio of Venus Remedies as of 04-Jun-2026 is 20.99.

What is the P/B ratio of Venus Remedies Ltd (VENUSREM)?

The latest standalone P/B ratio of Venus Remedies Ltd (VENUSREM) as of 04-Jun-2026 is 3.02.

What is the 52-week high and low of Venus Remedies Ltd (VENUSREM)?

The 52-week high of Venus Remedies Ltd (VENUSREM) is Rs. 1559.15 and the 52-week low is Rs. 417.65.

Venus Remedies Ltd (VENUSREM) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Venus Remedies Ltd (VENUSREM)
Brand: Venus Remedies

Key Metrics

Valuation Multiples

Market Cap

₹2,084 Cr.

Current Price

₹1,559.2

52-Week Low / High

₹418 / 1,559

TTM EPS

₹76.9

TTM Sales

₹770 Cr.

Book Value per Share

₹496.6

P/E Ratio

20.28

Higher than its 5-year historical median

Industry PE

46.5

Price to Book (P/B)

3.14

Higher than its 5-year historical median

Price to Sales (P/S)

2.71

Higher than its 5-year historical median

EV/EBITDA

12.85

Higher than its 5-year historical median

Dividend Yield

0.00%

Profitability Efficiency

Return on Equity (ROE)

8.64%

Underperforms industry median

Return on Capital Employed (ROCE)

13.17%

Outperforms industry median

Return on Assets (ROA)

6.75%

Operating Profit Margin

9.8%

Net Profit Margin

6.99%

Gross Profit Margin

13%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Improving versus 3-year growth rate

7.72%

Operating Profit Growth (1 Year)

Improving versus 3-year growth rate

6.59%

Net Profit Growth (1 Year)

Improving versus 3-year growth rate

59.04%

Asset Quality

Promoter Holding

41.76%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹650 Cr.

Equity

₹13.4 Cr.

Face Value

₹10

All Time Low / High

₹1.00 / 1484.95

Venus Remedies stock performance

Key Ratios

Check Before You Invest

Quality

Somewhat Good

Check detailed performance

Valuation

Overvalued

Check Valuation charts

Price Trend

Strong

Check Price chart

Q.1 Is Venus Remedies Ltd a good quality company?

Venus Remedies Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Venus Remedies Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Venus Remedies Ltd vs industry peers?

Venus Remedies Ltd revenue CAGR is 13.81%, compared to the industry median CAGR of 5.35%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Venus Remedies Ltd?

Promoters hold 41.76% of the Venus Remedies Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Venus Remedies Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 29.8% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	5.4%	2%	1.2%	-0.7%	0.9%	12.4%	7.9%	7.7%	8.7%	13.2%	-
Value Creation Index ⓘ	-0.6	-0.9	-0.9	-1.1	-0.9	-0.1	-0.4	-0.5	-0.4	-0.1	-
Growth Parameters ⓘ
Sales ⓘ	418	400	372	322	339	548	600	556	601	648	770
Sales YoY Gr.	-	-4.4%	-6.9%	-13.6%	5.4%	61.5%	9.5%	-7.4%	8.3%	7.7%	-
Adj EPS ⓘ	1.5	-15	-24.9	-20.1	-4.6	33.1	27.1	16	18.2	26.1	76.9
YoY Gr.	-	-1121.8%	NA	NA	NA	NA	-18%	-40.8%	13.5%	43.4%	-
BVPS (₹) ⓘ	382.5	314.9	293.2	269.4	262	313.2	329.5	344.4	364.7	419.7	496.6
Adj Net Profit ⓘ	1.7	-18.5	-30.8	-24.8	-5.7	40.8	36.2	21.4	24.3	34.9	103
Cash Flow from Ops. ⓘ	46.9	58.9	31.2	45.3	77.6	132	41.1	36.6	37.3	86.4	-
Debt/CF from Ops. ⓘ	7.2	5.3	9.8	6.6	2.8	0.4	1	1.2	1.1	0	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	5%	13.8%	2.6%	7.7%
Adj EPS ⓘ	37.7%	NA	-1.3%	43.4%
BVPSⓘ	1%	9.9%	8.4%	15.1%
Share Price	33.9%	36.4%	90.2%	254.9%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	0.4	-4.5	-8.2	-7.1	-1.7	11.3	8.6	4.8	5.1	6.7	16.8
Op. Profit Mgn % ⓘ	19.4	12.7	10.6	10.1	12	9.8	10.4	10.8	9.9	9.8	18.6
Net Profit Mgn % ⓘ	0.4	-4.6	-8.3	-7.7	-1.7	7.5	6	3.9	4	5.4	13.4
Debt to Equity ⓘ	0.8	0.8	0.9	0.9	0.7	0.1	0.1	0.1	0.1	0	0
Working Cap Days ⓘ	270	270	285	337	338	188	152	180	177	168	91
Cash Conv. Cycle ⓘ	153	152	153	170	147	70	56	83	87	72	60

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	418	400	372	322	339	548	600	556	601	648
Operating Expenses ⓘ +	337	349	333	289	299	494	538	495	542	584
Manufacturing Costs	20	47	40	26	26	27	36	38	35	43
Material Costs	239	227	205	182	174	341	387	331	355	379
Employee Cost	32	34	39	42	46	46	52	57	67	75
Other Costs ⓘ	46	41	48	39	53	80	62	70	85	88
Operating Profit ⓘ	81	51	39	33	41	54	62	60	60	64
Operating Profit Margin (%)	19.4%	12.7%	10.6%	10.1%	12.0%	9.8%	10.3%	10.8%	9.9%	9.8%
Other Income ⓘ +	2	4	2	6	5	20	8	10	12	21
Exceptional Items ⓘ	0	0	0	-9	-9	23	0	0	0	10
Interest ⓘ	38	36	36	25	13	13	0	0	0	0
Depreciation ⓘ	42	40	34	34	32	35	34	32	26	23
Profit Before Tax ⓘ	4	-22	-28	-30	-8	49	36	38	45	72
Tax ⓘ	2	-5	3	-1	2	-13	-4	11	16	27
Profit After Tax	2	-17	-31	-29	-10	62	41	27	28	45
PAT Margin (%)	0.4%	-4.3%	-8.2%	-8.9%	-3.0%	11.3%	6.8%	4.8%	4.7%	7.0%
Adjusted EPS (₹)	1.5	-13.8	-24.9	-23.2	-8.1	50.0	30.5	19.9	21.3	33.9
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Valuation of Venus Remedies - Consolidated

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	438	389	362	333	323	387	440	460	488	561
Share Capital ⓘ	11	12	12	12	12	12	13	13	13	13
Reserves ⓘ	426	376	350	320	311	374	427	447	474	548
Debt +	314	281	259	229	158	51	43	42	41	2
Long Term Debt	191	162	137	116	72	47	39	39	39	0
Short Term Debt	123	119	121	113	86	4	4	4	3	2
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	25	30	29	36	37	71	50	51	53	92
Others Liabilities ⓘ	66	66	101	135	126	47	46	48	45	61
Total Liabilities ⓘ	843	765	751	733	644	556	579	601	627	716
Fixed Assets
Net Fixed Assets ⓘ +	452	406	389	364	289	262	241	216	219	229
Gross Block	680	687	703	707	624	616	613	604	618	637
Accumulated Depreciation	227	280	314	343	335	355	372	388	399	407
CWIP ⓘ	80	66	65	65	25	25	25	26	21	26
Investments ⓘ	0	0	0	0	0	0	0	20	19	84
Inventories	143	141	138	143	141	120	126	120	122	100
Trade Receivables	62	47	47	38	31	32	39	77	80	112
Cash Equivalents	7	4	4	3	2	31	50	54	68	80
Others Assets ⓘ	98	101	107	120	156	86	98	88	98	83
Total Assets ⓘ	843	765	751	733	644	556	579	601	627	716

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	47	59	31	45	78	132	41	37	37	86
PBT ⓘ	4	-22	-28	-21	1	25	36	38	45	62
Adjustment ⓘ	56	71	66	61	42	22	26	23	20	15
Changes in Working Capital ⓘ	-13	10	-8	5	21	61	-22	-25	-12	25
Tax Paid ⓘ	0	0	0	0	0	0	0	0	-15	-15
Cash Flow From Investing Activity ⓘ +	3	-18	-11	-11	-5	56	-17	-51	-7	-76
Capex	-0	-23	0	-10	-8	58	-13	-8	-13	-18
Net Investments	0	0	0	0	0	-2	-5	-45	1	-63
Others ⓘ	3	4	-11	-1	3	1	1	2	5	5
Cash Flow From Financing Activity ⓘ +	-46	-44	-39	-35	-73	-162	-9	-1	-1	-1
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	-11	-12	-9	-5	-34	-88	-9	-0	-1	-1
Interest Paid ⓘ	-35	-33	-32	-22	-12	-7	-0	-0	-0	-0
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-0	1	2	-8	-28	-68	-0	0	0	-0
Net Cash Flow ⓘ	3	-4	-20	-1	-0	26	15	-15	29	9

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	0.38	-4.13	-8.18	-8.23	-3.05	17.4	9.85	5.9	6.01	8.64
ROCE (%)	5.35	2	1.17	-0.67	0.9	12.37	7.89	7.72	8.67	13.17
Asset Turnover Ratio	0.5	0.5	0.49	0.43	0.49	0.91	1.06	0.94	0.98	0.97
PAT to CFO Conversion(x)	23.5	N/A	N/A	N/A	N/A	2.13	1	1.37	1.32	1.91
Working Capital Days
Receivable Days	54.50	49.70	46.30	48.40	37	20.90	21.50	37.90	47.70	54.30
Inventory Days	124.90	129.50	136.60	159.30	152.70	86.90	74.70	80.70	73.30	62.60
Payable Days	41.90	44.10	52.60	65.50	76.10	57.90	57.30	55.70	53.50	69.90

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Venus Remedies Ltd FAQs

The current trading price of Venus Remedies on 04-Jun-2026 16:59 is ₹1,559.2.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Jun-2026 the market cap of Venus Remedies stood at ₹2,084.1 Cr

The latest P/E ratio of Venus Remedies as of 03-Jun-2026 is 20.99.

The latest P/B ratio of Venus Remedies as of 03-Jun-2026 is 3.02.

The 52-week high of Venus Remedies is ₹1,559.2 and the 52-week low is ₹417.6.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Venus Remedies is ₹769 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Venus Remedies Ltd is a average quality company.

The key valuation ratios of Venus Remedies Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Venus Remedies Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Venus Remedies Ltd

Venus Remedies incorporated in 1989, is a pharmaceutical manufacturing company. The company provides formulations in area of anti-biotics and oncological therapeutics.

Company has two manufacturing facilities located in India and Germany. Company manufactures Oncological and Cefelosporine Injectable products.

Its manufacturing facility located in India has received ISO 9001, ISO, 14001 and OHSAS 18001 for quality management. Its Germany facility follows EU-GMP norms.

Presently, the company has successfully made its presence in the markets of Philippines, Thailand, Malaysia, Cambodia, Burma, Vietnam, Sri Lanka, Pakistan, Bangladesh, Nepal, Uganda, Kenya, Botswana, Zimbabwe, Sudan, Mauritius, Yemen, Iraq, Russia, Belarus, Ukraine, Costa Rica, Venezuela, Guatemala, Peru, Colombia, Ecuador, Syria, Yeman, Togo, Saudi Arbia and Iraq.

Company has entered into strategic alliances with various pharmaceutical companies to launch its R&D based specialty products. It has tie-ups with companies namely IPCA Laboratories, Elder Pharmaceuticals, Shreya Lifesciences, Cadila Healthcare, Glenmark Pharmaceuticals, Marksans Pharma, Indoco Remedies, Karle Health Sciences, Lupin and Jagsonpal Pharmaceuticals.

Company also conducts in-house research and development activities that focuses Formulation Development, NDDS (Novel Drug Delivery System), new formulations of off patented chemicals and analytical and chemical research.

Products

The company is engaged in manufacturing products catering various segments such as Oncology, Cephalosporins, Carbapenems and Other Specialties, Intravenous Products, Vials/Lyophilized Injectables, Pre-Filled Syringes, Hormones, Ampoules and Biological Products.

Milestone/ Awards

2009
Venus Remedies - Product Patent for "TOBRACEF" granted in South Africa.
Venus Bags Another Product Patent from South Africa for POTENTOX.
2010
Venus Remedies receives GMP Certification from Botswana".
Venus Remedies ties up with IMTECH and Panjab Univ to develop Typhoid detection kits.
The Company has received approval from the Reserve Bank of India for rollover of FCCB USD 5mn, with YTM @4% with maturity till February 15, 2015.
Venus Remedies research Blockbuster "Sulbactomax" gets European Union Patent"
2011
Venus Remedies Ltd wins Gold Medal for TROIS under DST - Lockheed Martin India Innovation Growth Program 2011.
Venus launches its patented research product ACHNILâ€ in India.
Venus Remedies wins ""India Manufacturing Excellence Award 2011.
2012
Venus Remedies introduces "Ready-to-Use"" Single Vial Taxedol in India
Venus Remedies Limited introduced TROIS that is a research based, patent protected topical nano-emulsion product in India
The Company has won Manufacturing Award for its world class manufacturing and operational excellence at the "Industry 2.0 Manufacturing Innovation Conclave 2012.
Venus wins Patent award in Silver Category.

Venus Remedies Ltd (VENUSREM)

Venus Remedies Ltd (VENUSREM)

Venus Remedies stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Venus Remedies - Consolidated

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Venus Remedies Ltd FAQs

About Venus Remedies Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Venus Remedies Ltd (VENUSREM)

Venus Remedies Ltd (VENUSREM)

Venus Remedies stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Venus Remedies - Consolidated

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Venus Remedies Ltd FAQs

What is the share price of Venus Remedies?

What is the market cap of Venus Remedies?

What is the P/E ratio of Venus Remedies?

What is the P/B ratio of Venus Remedies?

What is the 52-week high and low of Venus Remedies?

What is the TTM revenue of Venus Remedies?

Is Venus Remedies Ltd a good quality company?

Is Venus Remedies Ltd undervalued or overvalued?

Is Venus Remedies Ltd a good buy now?

About Venus Remedies Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.